Patents by Inventor Michael Alexander Cowley
Michael Alexander Cowley has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20220202808Abstract: Disclosed are compositions for affecting weight loss comprising a first compound and a second compound, where the first compound is an opioid antagonist and the second compound causes increased agonism of a melanocortin 3 receptor (MC3-R) or a melanocortin 4 receptor (MC4-R) compared to normal physiological conditions. Also disclosed are methods of affecting weight loss, increasing energy expenditure, increasing satiety in an individual, or suppressing the appetite of an individual, comprising identifying an individual in need thereof and treating that individual to antagonize opioid receptor activity and to enhance ?-MSH activity.Type: ApplicationFiled: March 21, 2022Publication date: June 30, 2022Applicant: Nalpropion Pharmaceuticals LLCInventors: Eckard Weber, Michael Alexander Cowley
-
Patent number: 11278544Abstract: Disclosed are compositions for affecting weight loss comprising a first compound and a second compound, where the first compound is an opioid antagonist and the second compound causes increased agonism of a melanocortin 3 receptor (MC3-R) or a melanocortin 4 receptor (MC4-R) compared to normal physiological conditions. Also disclosed are methods of affecting weight loss, increasing energy expenditure, increasing satiety in an individual, or suppressing the appetite of an individual, comprising identifying an individual in need thereof and treating that individual to antagonize opioid receptor activity and to enhance ?-MSH activity.Type: GrantFiled: March 25, 2019Date of Patent: March 22, 2022Assignee: Nalpropion Pharmaceuticals LLCInventors: Eckard Weber, Michael Alexander Cowley
-
Publication number: 20210346469Abstract: Methods and compositions for treating a blood glucose condition involve identifying a suitable subject and administering an effective amount of a composition that contains one or more of an opioid antagonist, an anticonvulsant, and a psychotherapeutic agent. The compositions can include insulin. In some embodiments, such methods and compositions can be used to modulate a blood glucose level. In preferred embodiments, such methods and compositions are useful for increasing a subject's sensitivity to insulin.Type: ApplicationFiled: June 1, 2021Publication date: November 11, 2021Applicant: Nalpropion Pharmaceuticals LLCInventors: Michael Alexander Cowley, Anthony A. McKinney, Gary D. Tollefson
-
Publication number: 20210267968Abstract: Disclosed are compositions for reducing food cravings, comprising a first compound and a second compound, where the first compound is an opioid antagonist and the second compound is an ?-MSH agonist. Also disclosed are methods of reducing food cravings, comprising identifying an individual in need thereof and treating that individual to antagonize opioid receptor activity and to enhance ?-MSH activity.Type: ApplicationFiled: May 13, 2021Publication date: September 2, 2021Applicant: Nalpropion Pharmaceuticals LLCInventors: Anthony A. McKinney, Gary D. Tollefson, Michael Alexander Cowley
-
Publication number: 20190231852Abstract: Methods and compositions for treating a blood glucose condition involve identifying a suitable subject and administering an effective amount of a composition that contains one or more of an opioid antagonist, an anticonvulsant, and a psychotherapeutic agent. The compositions can include insulin. In some embodiments, such methods and compositions can be used to modulate a blood glucose level. In preferred embodiments, such methods and compositions are useful for increasing a subject's sensitivity to insulin.Type: ApplicationFiled: April 8, 2019Publication date: August 1, 2019Inventors: Michael Alexander Cowley, Anthony A. McKinney, Gary D. Tollefson
-
Publication number: 20190216799Abstract: Disclosed are compositions for affecting weight loss comprising a first compound and a second compound, where the first compound is an opioid antagonist and the second compound causes increased agonism of a melanocortin 3 receptor (MC3-R) or a melanocortin 4 receptor (MC4-R) compared to normal physiological conditions. Also disclosed are methods of affecting weight loss, increasing energy expenditure, increasing satiety in an individual, or suppressing the appetite of an individual, comprising identifying an individual in need thereof and treating that individual to antagonize opioid receptor activity and to enhance ?-MSH activity.Type: ApplicationFiled: March 25, 2019Publication date: July 18, 2019Inventors: Eckard Weber, Michael Alexander Cowley
-
Patent number: 10238647Abstract: Disclosed are compositions for affecting weight loss comprising a first compound and a second compound, where the first compound is an opioid antagonist and the second compound causes increased agonism of a melanocortin 3 receptor (MC3-R) or a melanocortin 4 receptor (MC4-R) compared to normal physiological conditions. Also disclosed are methods of affecting weight loss, increasing energy expenditure, increasing satiety in an individual, or suppressing the appetite of an individual, comprising identifying an individual in need thereof and treating that individual to antagonize opioid receptor activity and to enhance ?-MSH activity.Type: GrantFiled: September 26, 2016Date of Patent: March 26, 2019Assignee: Nalpropion Pharmaceuticals, Inc.Inventors: Eckard Weber, Michael Alexander Cowley
-
Publication number: 20170007598Abstract: Disclosed are compositions for affecting weight loss comprising a first compound and a second compound, where the first compound is an opioid antagonist and the second compound causes increased agonism of a melanocortin 3 receptor (MC3-R) or a melanocortin 4 receptor (MC4-R) compared to normal physiological conditions. Also disclosed are methods of affecting weight loss, increasing energy expenditure, increasing satiety in an individual, or suppressing the appetite of an individual, comprising identifying an individual in need thereof and treating that individual to antagonize opioid receptor activity and to enhance ?-MSH activity.Type: ApplicationFiled: September 26, 2016Publication date: January 12, 2017Inventors: Eckard Weber, Michael Alexander Cowley
-
Publication number: 20150141452Abstract: Disclosed are compositions for affecting weight loss comprising a first compound and a second compound, where the first compound is an opioid antagonist and the second compound causes increased agonism of a melanocortin 3 receptor (MC3-R) or a melanocortin 4 receptor (MC4-R) compared to normal physiological conditions. Also disclosed are methods of affecting weight loss, increasing energy expenditure, increasing satiety in an individual, or suppressing the appetite of an individual, comprising identifying an individual in need thereof and treating that individual to antagonize opioid receptor activity and to enhance ?-MSH activity.Type: ApplicationFiled: January 21, 2015Publication date: May 21, 2015Inventors: Eckard Weber, Michael Alexander Cowley
-
Publication number: 20120309677Abstract: The invention relates to methods and compositions for reducing blood glucose levels in hyperglycaemic subjects. The methods and compositions may therefore be suitable for treating a disease or condition associated with hyperglycaemia such as, for example, obesity (particularly diet induced obesity (DIO)), weight gain, Type II diabetes mellitus, insulin sensitivity, impaired glucose tolerance and inflammation. In some embodiments, the methods comprise administering a melanocortin-5 receptor (MC5R) agonist to one or more skeletal muscle cells of the subject. Preferred MC5R agonists are those that specifically activate MC5R and/or enhance expression of MC5R, such as the melanocortin analogue, Ac-Nle-c[Asp-Pro-D-Nal(2?)-Arg-Trp-Lys]-NH2.Type: ApplicationFiled: January 25, 2011Publication date: December 6, 2012Applicant: Monash UniversityInventors: Michael Alexander Cowley, Pablo Jose Enriori, Russell Deputy Brown, Iain James Clarke, Belinda Anne Henry, Maria Cecilia Garcia-Rudaz
-
Publication number: 20120010232Abstract: Disclosed are compositions for affecting weight loss comprising a first compound and a second compound, where the first compound is an opioid antagonist and the second compound causes increased agonism of a melanocortin 3 receptor (MC3-R) or a melanocortin 4 receptor (MC4-R) compared to normal physiological conditions. Also disclosed are methods of affecting weight loss, increasing energy expenditure, increasing satiety in an individual, or suppressing the appetite of an individual, comprising identifying an individual in need thereof and treating that individual to antagonize opioid receptor activity and to enhance ?-MSH activity.Type: ApplicationFiled: September 22, 2011Publication date: January 12, 2012Applicant: Orexigen Therapeutics, Inc.Inventors: Eckard Weber, Michael Alexander Cowley
-
Publication number: 20100190793Abstract: Disclosed are compositions for affecting weight loss comprising a first compound and a second compound, where the first compound is an opioid antagonist and the second compound causes increased agonism of a melanocortin 3 receptor (MC3-R) or a melanocortin 4 receptor (MC4-R) compared to normal physiological conditions. Also disclosed are methods of affecting weight loss, increasing energy expenditure, increasing satiety in an individual, or suppressing the appetite of an individual, comprising identifying an individual in need thereof and treating that individual to antagonize opioid receptor activity and to enhance ?-MSH activity.Type: ApplicationFiled: March 31, 2010Publication date: July 29, 2010Applicant: Orexigen Therapeutics, Inc.Inventors: Eckard Weber, Michael Alexander Cowley
-
Patent number: 7462626Abstract: Disclosed are compositions for affecting weight loss comprising a first compound and a second compound, where the first compound is an opioid antagonist and the second compound causes increased agonism of a melanocortin 3 receptor (MC3-R) or a melanocortin 4 receptor (MC4-R) compared to normal physiological conditions. Also disclosed are methods of affecting weight loss, increasing energy expenditure, increasing satiety in an individual, or suppressing the appetite of an individual, comprising identifying an individual in need thereof and treating that individual to antagonize opioid receptor activity and to enhance ?-MSH activity.Type: GrantFiled: February 17, 2006Date of Patent: December 9, 2008Assignee: Orexigen Therapeutics, Inc.Inventors: Eckard Weber, Michael Alexander Cowley
-
Patent number: 7375111Abstract: Disclosed are compositions for affecting weight loss comprising a first compound and a second compound, where the first compound is an opioid antagonist and the second compound causes increased agonism of a melanocortin 3 receptor (MC3-R) or a melanocortin 4 receptor (MC4-R) compared to normal physiological conditions. Also disclosed are methods of affecting weight loss, increasing energy expenditure, increasing satiety in an individual, or suppressing the appetite of an individual, comprising identifying an individual in need thereof and treating that individual to antagonize opioid receptor activity and to enhance ?-MSH activity.Type: GrantFiled: April 21, 2004Date of Patent: May 20, 2008Assignee: Orexigen Therapeutics, Inc.Inventors: Eckard Weber, Michael Alexander Cowley
-
Publication number: 20040254208Abstract: Disclosed are compositions for affecting weight loss comprising a first compound and a second compound, where the first compound is an opioid antagonist and the second compound causes increased agonism of a melanocortin 3 receptor (MC3-R) or a melanocortin 4 receptor (MC4-R) compared to normal physiological conditions. Also disclosed are methods of affecting weight loss, increasing energy expenditure, increasing satiety in an individual, or suppressing the appetite of an individual, comprising identifying an individual in need thereof and treating that individual to antagonize opioid receptor activity and to enhance &agr;-MSH activity.Type: ApplicationFiled: April 21, 2004Publication date: December 16, 2004Inventors: Eckard Weber, Michael Alexander Cowley